Literature DB >> 21321604

Osteoclast activity modulates B-cell development in the bone marrow.

Anna Mansour1, Adrienne Anginot, Stéphane J C Mancini, Claudine Schiff, Georges F Carle, Abdelilah Wakkach, Claudine Blin-Wakkach.   

Abstract

B-cell development is dependent on the interactions between B-cell precursors and bone marrow stromal cells, but the role of osteoclasts (OCLs) in this process remains unknown. B lymphocytopenia is a characteristic of osteopetrosis, suggesting a modulation of B lymphopoiesis by OCL activity. To address this question, we first rescued OCL function in osteopetrotic oc/oc mice by dendritic cell transfer, leading to a restoration of both bone phenotype and B-cell development. To further explore the link between OCL activity and B lymphopoiesis, we induced osteopetrosis in normal mice by injections of zoledronic acid (ZA), an inhibitor of bone resorption. B-cell number decreased specifically in the bone marrow of ZA-treated mice. ZA did not directly affect B-cell differentiation, proliferation and apoptosis, but induced a decrease in the expression of CXCL12 and IL-7 by stromal cells, associated with reduced osteoblastic engagement. Equivalent low osteoblastic engagement in oc/oc mice confirmed that it resulted from the reduced OCL activity rather than from a direct effect of ZA on osteoblasts. These dramatic alterations of the bone microenvironment were disadvantageous for B lymphopoiesis, leading to retention of B-cell progenitors outside of their bone marrow niches in the ZA-induced osteopetrotic model. Altogether, our data revealed that OCLs modulate B-cell development in the bone marrow by controlling the bone microenvironment and the fate of osteoblasts. They provide novel basis for the regulation of the retention of B cells in their niche by OCL activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321604      PMCID: PMC3193501          DOI: 10.1038/cr.2011.21

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  53 in total

1.  RANK is essential for osteoclast and lymph node development.

Authors:  W C Dougall; M Glaccum; K Charrier; K Rohrbach; K Brasel; T De Smedt; E Daro; J Smith; M E Tometsko; C R Maliszewski; A Armstrong; V Shen; S Bain; D Cosman; D Anderson; P J Morrissey; J J Peschon; J Schuh
Journal:  Genes Dev       Date:  1999-09-15       Impact factor: 11.361

2.  The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment.

Authors:  Q Ma; D Jones; T A Springer
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

3.  Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development.

Authors:  Matthew A Inlay; Deepta Bhattacharya; Debashis Sahoo; Thomas Serwold; Jun Seita; Holger Karsunky; Sylvia K Plevritis; David L Dill; Irving L Weissman
Journal:  Genes Dev       Date:  2009-10-15       Impact factor: 11.361

4.  Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells.

Authors:  Fabian von Knoch; Claude Jaquiery; Marc Kowalsky; Stefan Schaeren; Claude Alabre; Ivan Martin; Harry E Rubash; Arun S Shanbhag
Journal:  Biomaterials       Date:  2005-12       Impact factor: 12.479

5.  Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice.

Authors:  A Naito; S Azuma; S Tanaka; T Miyazaki; S Takaki; K Takatsu; K Nakao; K Nakamura; M Katsuki; T Yamamoto; J Inoue
Journal:  Genes Cells       Date:  1999-06       Impact factor: 1.891

6.  The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.

Authors:  E van beek; C Löwik; G van der Pluijm; S Papapoulos
Journal:  J Bone Miner Res       Date:  1999-05       Impact factor: 6.741

7.  Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.

Authors:  Alessandro Corso; Eleonora Ferretti; Monia Lunghi; Patrizia Zappasodi; Silvia Mangiacavalli; Mara De Amici; Chiara Rusconi; Marzia Varettoni; Mario Lazzarino
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

8.  Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces.

Authors:  S Colucci; V Minielli; G Zambonin; N Cirulli; G Mori; M Serra; V Patella; A Zambonin Zallone; M Grano
Journal:  Calcif Tissue Int       Date:  1998-09       Impact factor: 4.333

9.  A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution.

Authors:  K Kawabata; M Ujikawa; T Egawa; H Kawamoto; K Tachibana; H Iizasa; Y Katsura; T Kishimoto; T Nagasawa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation.

Authors:  Libuse Tauchmanovà; Patrizia Ricci; Bianca Serio; Gaetano Lombardi; Annamaria Colao; Bruno Rotoli; Carmine Selleri
Journal:  J Clin Endocrinol Metab       Date:  2004-11-16       Impact factor: 5.958

View more
  28 in total

1.  Chemotactic and immunoregulatory properties of bone cells are modulated by endotoxin-stimulated lymphocytes.

Authors:  Hrvoje Cvija; Natasa Kovacic; Vedran Katavic; Sanja Ivcevic; Hector Leonardo Aguila; Ana Marusic; Danka Grcevic
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

2.  Effects of denosumab on peripheral lymphocyte subpopulations.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Francesco Ghellere; Gaia Tripi; Riccardo Ortolani; Roberta Zanotti; Davide Gatti
Journal:  Endocrine       Date:  2015-08-20       Impact factor: 3.633

3.  Macrophage colony-stimulating factor pretreatment of bone marrow progenitor cells regulates osteoclast differentiation based upon the stage of myeloid development.

Authors:  Xuehui Yang; Shivangi Pande; Cameron Scott; Robert Friesel
Journal:  J Cell Biochem       Date:  2019-02-25       Impact factor: 4.429

4.  Osteoclasts and hematopoiesis.

Authors:  Anna Teti
Journal:  Bonekey Rep       Date:  2012-03-28

5.  RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice.

Authors:  Yuko Fujiwara; Marilina Piemontese; Yu Liu; Jeff D Thostenson; Jinhu Xiong; Charles A O'Brien
Journal:  J Biol Chem       Date:  2016-10-12       Impact factor: 5.157

6.  Tissue-Engineered Model of Human Osteolytic Bone Tumor.

Authors:  Aranzazu Villasante; Alessandro Marturano-Kruik; Samuel T Robinson; Zen Liu; X Edward Guo; Gordana Vunjak-Novakovic
Journal:  Tissue Eng Part C Methods       Date:  2017-02       Impact factor: 3.056

7.  Klotho deficiency disrupts hematopoietic stem cell development and erythropoiesis.

Authors:  Sangeetha Vadakke Madathil; Lindsay M Coe; Carla Casu; Despina Sitara
Journal:  Am J Pathol       Date:  2014-01-08       Impact factor: 4.307

8.  Absence of sclerostin adversely affects B-cell survival.

Authors:  Corey J Cain; Randell Rueda; Bryce McLelland; Nicole M Collette; Gabriela G Loots; Jennifer O Manilay
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

Review 9.  Normal and leukemic stem cell niches: insights and therapeutic opportunities.

Authors:  Koen Schepers; Timothy B Campbell; Emmanuelle Passegué
Journal:  Cell Stem Cell       Date:  2015-03-05       Impact factor: 24.633

10.  Osteoclasts are not crucial for hematopoietic stem cell maintenance in adult mice.

Authors:  Carmen Flores; Ilana Moscatelli; Christian S Thudium; Natasja Stæhr Gudmann; Jesper S Thomsen; Annemarie Brüel; Morten A Karsdal; Kim Henriksen; Johan Richter
Journal:  Haematologica       Date:  2013-10-04       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.